SI-BONE, Inc. (SIBN)
| Market Cap | 882.25M +38.4% |
| Revenue (ttm) | 213.60M +15.3% |
| Net Income | -14.63M |
| EPS | -0.33 |
| Shares Out | 44.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 442,585 |
| Open | 20.24 |
| Previous Close | 20.10 |
| Day's Range | 19.68 - 20.26 |
| 52-Week Range | 11.48 - 21.89 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 25.22 (+28.12%) |
| Est. Earnings | Nov 9, 2026 |
About SIBN
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the impla... [Read more]
Financial Performance
In 2025, SI-BONE's revenue was $200.93 million, an increase of 20.19% compared to the previous year's $167.18 million. Losses were -$18.90 million, -38.85% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for SIBN stock is "Strong Buy." The 12-month stock price target is $25.22, which is an increase of 28.12% from the latest price.
News
SI-Bone announces FDA 510(k) clearance of iFuse Granite Onyx System
SI-Bone (SIBN) announced FDA 510(k) clearance for the iFuse Granite Onyx System. This is SI-Bone’s first product addressing the problem of compromised bone which is intended for use outside the…
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density b...
SI-BONE Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has evolved into a multi-product platform targeting the pelvis and spine, achieving strong growth and profitability through innovation, expanded reimbursement, and a robust product pipeline. Durable tailwinds from new DRGs, product launches, and operational efficiency are expected to accelerate growth and profitability in the coming years.
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bon...
SI-Bone price target raised to $25 from $24 at UBS
UBS analyst Patrick Wood raised the firm’s price target on SI-Bone (SIBN) to $25 from $24 and keeps a Buy rating on the shares. SI-Bone posted a “solid” print and…
SI-Bone price target raised to $20 from $18 at TD Cowen
TD Cowen analyst Mathew Blackman raised the firm’s price target on SI-Bone (SIBN) to $20 from $18 and keeps a Buy rating on the shares. The firm said with strong…
SI-Bone price target raised to $23 from $21 at Truist
Truist raised the firm’s price target on SI-Bone (SIBN) to $23 from $21 and keeps a Buy rating on the shares. The company delivered accelerating revenue growth, stronger procedures, and…
SI-Bone sees FY26 revenue $231M-$233M, consensus $231.79M
The company is maintaining FY26 gross margin guidance at ~79%, and updating operating expenses guidance to now be ~12% compared to the prior guidance of ~12.5%.
SI-Bone reports Q2 EPS (9c), consensus (15c)
Reports Q2 revenue $56.0M, consensus $55.4M. “Our accelerating growth and expanding profitability reinforces our conviction in the demand for our superior platform technologies and the significant run...
SI-BONE Earnings Call Transcript: Q2 2026
Q2 2026 delivered 15% revenue growth, strong operating leverage, and a narrowed net loss, driven by broad-based demand and new product momentum. Guidance was raised, with multiple catalysts expected in H2 2026, including a new breakthrough device launch and higher reimbursement.
SI-BONE Earnings release: Q2 2026
SI-BONE released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
SI-BONE Slides: Q2 2026
SI-BONE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
SI-BONE Quarterly report: Q2 2026
SI-BONE has published its Q2 2026 quarterly earnings report on August 3, 2026.
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
Delivered ~15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base
SI-Bone initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of SI-Bone (SIBN) with a Buy rating and $24 price target The firm anticipates an innovation supercycle, the analyst tells investors in a research…
SI-Bone initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of SI-Bone (SIBN) with a Buy rating and $24 price target
SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026
SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bon...
SI-Bone price target raised to $21 from $18 at Truist
Truist raised the firm’s price target on SI-Bone (SIBN) to $21 from $18 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its ...
SI-BONE Transcript: Truist Securities MedTech Conference 2026
The company has evolved into a multi-product platform targeting a $3.5B TAM, with strong growth in SI joint, trauma, and pelvic fixation markets. Physician base and sales force expansion, new product launches, and partnerships like Smith+Nephew are expected to drive accelerated growth and improved reimbursement through 2028.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bon...
SI-BONE Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, all of which were approved. No questions were raised, and a quorum was established with nearly 88% of shares represented. Final voting results will be filed on Form 8-K.
SI-Bone management to meet with Needham
Meeting to be held in Boston on June 1 and in New York on June 2 hosted by Needham.
SI-Bone price target lowered to $18 from $22 at TD Cowen
TD Cowen analyst Mathew Blackman lowered the firm’s price target on SI-Bone (SIBN) to $18 from $22 and keeps a Buy rating on the shares. The firm said sales and…
SI-BONE Transcript: Bank of America Global Healthcare Conference 2026
Momentum is driven by innovation, expanding physician adoption, and strategic partnerships, with new products and reimbursement changes expected to accelerate growth and profitability through 2026 and beyond. Gross margins remain strong near 80%, and operating leverage is set to improve.